Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Int J STD AIDS ; 23(12): 865-9, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23258826

RESUMEN

To estimate the cost of the first combination antiretroviral drug therapy (cART) in HIV-infected patients and to determine factors associated with expensive prescriptions, 1698 patients starting cART between September 2002 and September 2007 were selected from the Dat'AIDS cohort. A multivariate linear regression model was used to assess associations between the cost of first cART and patient characteristics, clinical centre and cART adequacy. At cART initiation, the median age was 39 years, median CD4 count was 223 cells/mm(3), median viral load (VL) was 5.2 log copies/mL and 18.3% presented with AIDS. cART was concordant with the French guidelines in 88.7%. The mean cost of cART varied from €26.69/day/person in 2002-2003 to €32.23 in 2006-2007 (P < 0.0001), cost was associated with previous AIDS diagnosis (€31.83/day/person) versus (29.49; P < 0.0001), baseline VL > 5 log copies/mL (€30.99/day/person) versus (28.33; P < 0.0001) and centre. cART regimen not concordant with guidelines were more expensive (€38.31/day/person) versus (29.07; P < 0.0001). After adjusting for the year of initiation, the previous AIDS diagnosis, VL and recommended cART regimen, differences were still found between centres (from €27.81/day/person) to (33.12; P < 0.0001). Cost should be considered when choosing a first cART regimen, especially when considering clinically equivalent regimens.


Asunto(s)
Antirretrovirales/economía , Infecciones por VIH/economía , Adulto , Antirretrovirales/uso terapéutico , Costos de los Medicamentos , Prescripciones de Medicamentos/economía , Quimioterapia Combinada/economía , Quimioterapia Combinada/métodos , Femenino , Francia , Infecciones por VIH/tratamiento farmacológico , Humanos , Modelos Lineales , Masculino , Persona de Mediana Edad , Estudios Prospectivos
3.
Bioprocess Biosyst Eng ; 28(1): 55-61, 2005 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16195896

RESUMEN

Spiramycin production by Streptomyces ambofaciens Sp181110 with glucose as the carbon source was studied under a controlled nutritional environment. In a batch culture, the glucose excess after ammonium depletion led to pyruvate and alpha-ketoglutarate accumulation. 85 mg/l of spiramycin were produced in less than 70 h during the stationary and maintenance phase on these acids after glucose exhaustion. Fed-batch strategy was designed to study spiramycin production without by-product formation and glucose accumulation. In these conditions, up to 150 mg/l were produced in less than 80 h during the stationary phase on glucose. The antibiotic titre was found independent of the glucose feeding under carbon limitation and the importance of putative intracellular reserves formed after nutrient exhaustion was suggested. Besides, spiramycin production was not inhibited by the limiting flux of glucose.


Asunto(s)
Reactores Biológicos/microbiología , Técnicas de Cultivo de Célula/métodos , Glucosa/metabolismo , Modelos Biológicos , Espiramicina/biosíntesis , Streptomyces/crecimiento & desarrollo , Streptomyces/metabolismo , Biomasa , Proliferación Celular , Simulación por Computador , Especificidad de la Especie , Streptomyces/clasificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA